HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CARB survey

This article was originally published in The Rose Sheet

Executive Summary

Nearly 100 beauty and personal care categories are included on California Air Resources Board's preliminary draft list of products that will be reviewed as part of the 2003 Consumer & Commercial Products Survey. CARB released the list Aug. 18 for discussion at a public meeting Aug. 25. Although survey will be "comprehensive" rather than "targeted," as the 2001 survey was, CARB notes the preliminary list of categories "does not necessarily represent the final list of categories that will be surveyed." Personal care products listed on the draft include antiperspirants and deodorants, body, hand and face cleaners, facial and body treatments, fragrance products, hair care products, makeup, nail care products, oral care products and shaving products among others. Survey results will be used to determine new categories for voluntary organic compound emission reductions...

You may also be interested in...



CARB Consumer Products Survey Release Scheduled For October

The California Air Resources Board's decision to forego category definitions for consumer products in its 2003 Consumer & Commercial Products Survey could prove to be inefficient, the Cosmetic, Toiletry and Fragrance Association said during a stakeholder workgroup meeting held Aug. 25 in Sacramento, Calif

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel